ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Hong Kong · Delayed Price · Currency is HKD

3.125

-0.040 (-1.26%)

Oct 9, 2026, 4:08 PM HKT

Market Cap	1.34B -80.2%
Revenue (ttm)	170.32M +25.6%
Net Income	-265.74M
EPS	-0.63
Shares Out	429.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	298,400
Open	3.170
Previous Close	3.165
Day's Range	3.050 - 3.200
52-Week Range	2.800 - 16.800
Beta	0.24
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HKG:1541

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical tria... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 197

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 1541

Full Company Profile

Financial Performance

In 2025, HKG:1541's revenue was 154.29 million, an increase of 108.09% compared to the previous year's 74.15 million. Losses were -218.58 million, -30.80% less than in 2024.

Financial numbers in CNY Financial Statements